Patents by Inventor Mark T. Marino

Mark T. Marino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhalable dry powder pharmaceutical composition
    Publication number: 20230293436
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: March 15, 2022
    Publication date: September 21, 2023
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Inhalable dry powder pharmaceutical composition
    Patent number: 11304992
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: April 19, 2022
    Assignee: MANNKIND CORPORATION
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • DRY POWDER DRUG DELIVERY SYSTEM
    Publication number: 20210244897
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
    Type: Application
    Filed: April 29, 2021
    Publication date: August 12, 2021
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino
  • LIPOSOMAL TAXANES FOR TREATMENT OF SCLC
    Publication number: 20200390702
    Abstract: Methods for therapy for a small cell lung cancer (SCLC), which may or may not respond to a first-line therapy or that progresses following cessation of a first-line chemotherapy is provided. Some methods include the administration of composition that comprises a protein-stabilized form of docetaxel, optionally in conjunction with a regimen of supportive care.
    Type: Application
    Filed: August 6, 2018
    Publication date: December 17, 2020
    Inventor: Mark T. Marino
  • METHOD FOR TREATING HYPERGLYCEMIA WITH GLP-1
    Publication number: 20200147180
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: December 19, 2019
    Publication date: May 14, 2020
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • DRY POWDER DRUG DELIVERY SYSTEM
    Publication number: 20190262557
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
    Type: Application
    Filed: May 13, 2019
    Publication date: August 29, 2019
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino
  • Dry powder drug delivery system
    Patent number: 10342938
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: July 9, 2019
    Assignee: MannKind Corporation
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino
  • METHOD FOR TREATING HYPERGLYCEMIA WITH GLP-1
    Publication number: 20170304404
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: July 3, 2017
    Publication date: October 26, 2017
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Dry powder drug delivery system and methods
    Patent number: 9662461
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, endocrine disease such as diabetes and/or obesity.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 30, 2017
    Assignee: MannKind Corporation
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl Sahi, Christine Billings, Mark T. Marino
  • DRY POWDER DRUG DELIVERY SYSTEM
    Publication number: 20160287820
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
    Type: Application
    Filed: June 14, 2016
    Publication date: October 6, 2016
    Inventors: Chad C. Smutney, Beniot Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino
  • DRY POWDER DRUG DELIVERY SYSTEM AND METHODS
    Publication number: 20160243322
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, endocrine disease such as diabetes and/or obesity.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 25, 2016
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl Sahi, Christine Billings, Mark T. Marino
  • Dry powder drug delivery system
    Patent number: 9393372
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: July 19, 2016
    Assignee: MannKind Corporation
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino
  • Dry powder drug delivery system and methods
    Patent number: 9358352
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, endocrine disease such as diabetes and/or obesity.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: June 7, 2016
    Assignee: MannKind Corporation
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl Sahi, Christine Billings, Mark T. Marino
  • METHOD FOR TREATING HYPERGLYCEMIA WITH GLP-1
    Publication number: 20150283213
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: May 22, 2015
    Publication date: October 8, 2015
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Method for treating hyperglycemia with GLP-1
    Patent number: 9078866
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with Type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: July 14, 2015
    Assignee: MannKind Corporation
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • METHOD FOR TREATING HYPERGLYCEMIA
    Publication number: 20150080298
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Application
    Filed: November 19, 2014
    Publication date: March 19, 2015
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Method for treating hyperglycemia
    Patent number: 8921311
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: December 30, 2014
    Assignee: MannKind Corporation
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • DRY POWDER DRUG DELIVERY SYSTEM
    Publication number: 20130291867
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation.
    Type: Application
    Filed: July 2, 2013
    Publication date: November 7, 2013
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino
  • Dry powder drug delivery system
    Patent number: 8485180
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of endocrine disease, for example, diabetes and/or obesity.
    Type: Grant
    Filed: March 4, 2010
    Date of Patent: July 16, 2013
    Assignee: MannKind Corporation
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl R. Sahi, Christine Billings, Mark T. Marino
  • Dry Powder Drug Delivery System and Methods
    Publication number: 20130104887
    Abstract: A pulmonary drug delivery system is disclosed, including a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, small organic molecules, peptides and proteins, including, insulin and glucagon-like peptide 1 for the treatment of disease and disorders, for example, endocrine disease such as diabetes and/or obesity.
    Type: Application
    Filed: June 21, 2011
    Publication date: May 2, 2013
    Applicant: MANNKIND CORPORATION
    Inventors: Chad C. Smutney, Benoit Adamo, John M. Polidoro, P. Spencer Kinsey, Dennis Overfield, Carl Sahi, Christine Billings, Mark T. Marino